EVISA Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:

Glossary


spiroplatin


Spiroplatin is a second generation metallodrug and analgue for cisplatin, developed for cancer therapy. Spiroplatin induces DNA cross-links, thereby inhibiting DNA replication and RNA and protein synthesis. Similar to other platinum compounds, this agent has been shown to be mutagenic and carcinogenic.
 
IUPAC name: aqua-1,1-bis(aminomethyl)-cyclohexanesulfatoplatinum(II)


Back








Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )